Renaissance Technologies LLC Sells 20,200 Shares of iShares Biotechnology ETF $IBB

Renaissance Technologies LLC reduced its position in iShares Biotechnology ETF (NASDAQ:IBB) by 76.5% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 6,200 shares of the financial services provider’s stock after selling 20,200 shares during the period. Renaissance Technologies LLC’s holdings in iShares Biotechnology ETF were worth $1,047,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Basepoint Wealth LLC acquired a new position in shares of iShares Biotechnology ETF during the fourth quarter valued at $26,000. Cary Street Partners Financial LLC acquired a new stake in iShares Biotechnology ETF in the fourth quarter worth about $29,000. Darwin Wealth Management LLC acquired a new stake in iShares Biotechnology ETF in the second quarter worth about $25,000. Caitlin John LLC bought a new stake in iShares Biotechnology ETF during the 4th quarter worth about $34,000. Finally, Cornerstone Planning Group LLC bought a new stake in iShares Biotechnology ETF during the 4th quarter worth about $35,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

iShares Biotechnology ETF stock opened at $198.26 on Friday. iShares Biotechnology ETF has a 1 year low of $136.89 and a 1 year high of $201.72. The company’s 50-day moving average is $186.87 and its two-hundred day moving average is $176.26.

iShares Biotechnology ETF Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 18th. Investors of record on Monday, June 15th were paid a dividend of $0.0238 per share. This represents a $0.10 dividend on an annualized basis and a dividend yield of 0.0%. The ex-dividend date of this dividend was Monday, June 15th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.